{"links":{"html":"https://www.erudio.com/reports/quintessential-2-nct06615479","json":"https://www.erudio.com/reports/quintessential-2-nct06615479.json","markdown":"https://www.erudio.com/reports/quintessential-2-nct06615479.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"quintessential-2-06615479"}},"request":"https://www.erudio.com/contact?report=quintessential-2-06615479"},"offer":{"cited_commentary_sources":8,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a licence key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, to join with NPI-keyed systems such as a CRM. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":750,"identity_verified_people":4,"optional":true,"price_per_verified_person_usd":15,"price_usd":60,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One licence key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"quintessential-2-nct06615479"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the licence key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=quintessential-2-06615479","people":"Tom and Audun, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/quintessential-2-nct06615479","renewal":"Subscriptions are prepaid and do not renew automatically.","terms":"https://www.erudio.com/terms"},"size":"focused","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-09T22:31:55.117816Z","notify_subscribers":false,"status":"new","summary":{"reason":"Initial accepted edition has no weekly change log.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":0},"aspects":[{"claim_count":10,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":5,"title":"Primary endpoint: Progression Free Survival (PFS)"},{"claim_count":8,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":2,"title":"Primary endpoint: Minimal residual disease (MRD)-negativity in complete response (CR)"},{"claim_count":7,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":6,"title":"Secondary endpoints"},{"claim_count":15,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":6,"title":"Population and setting"},{"claim_count":8,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":4,"title":"The comparison"},{"claim_count":18,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.interventions","source_count":6,"title":"Safety and tolerability"},{"claim_count":7,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":5,"title":"Design and conduct"},{"claim_count":38,"coverage":"discussed","id":"A1","source_count":4,"title":"Antigen selection and resistance-informed sequencing"},{"claim_count":34,"coverage":"discussed","id":"A2","source_count":3,"title":"Earlier CAR-T, durable remission and treatment-free goals"},{"claim_count":25,"coverage":"discussed","id":"A3","source_count":7,"title":"Referral, travel, center access and participation constraints"},{"claim_count":15,"coverage":"discussed","id":"A4","source_count":2,"title":"Pre-apheresis holding versus pre-infusion bridging"},{"claim_count":30,"coverage":"discussed","id":"A5","source_count":2,"title":"CAR-T deferral and CELMoD-based alternative regimens"},{"claim_count":32,"coverage":"discussed","id":"A6","source_count":2,"title":"Off-the-shelf alternatives, ineligibility and selective withholding"}],"counts":{"cited_sources":8,"claims_by_expression_type":{"comparison":31,"experience":29,"interpretation":36,"opinion":35,"question":24,"restatement":37,"uncertainty":14,"unspecified":21},"claims_by_kind":{"attributed_opinion":1,"interpretation":15,"limitation":9,"source_observation":202},"evidence_units":101,"findings":9,"people_cited":13,"people_identity_verified":4,"people_total":6,"screened_sources":10,"verified_claims":227},"depth":"thin","depth_rule":"thin if verified claims <30, findings <5, or cited sources <10; rich if verified claims >=100, findings >=8, and cited sources >=30; otherwise standard","findings_index":[{"id":"F1","title":"An attractive non-BCMA option, with superiority still an open question"},{"id":"F2","title":"Less persistent GPRC5D toxicity does not resolve the non-ICANS neurologic signal"},{"id":"F3","title":"Post-BCMA placement is attractive, but antigen switching is not an automatic rule"},{"id":"F4","title":"Earlier CAR-T is framed as a remission opportunity, not a guaranteed cure"},{"id":"F5","title":"Referral and access remain limiting even when enthusiasm and center capacity improve"},{"id":"F6","title":"Holding and bridging therapy have different purposes and different constraints"},{"id":"F7","title":"CAR-T deferral prompts risk-adapted alternatives, with substantial supportive-care qualifications"},{"id":"F8","title":"Off-the-shelf alternatives depend on eligibility, sequencing and treatment burden"},{"id":"F9","title":"MRD is discussed as an earlier evidence signal and a treatment-stop question—not a stopping rule"}],"medical_affairs_question":"What comparative benefit would distinguish target diversification from a clinically meaningful improvement over the trial's standard-care options?","sections":{"analysis":[{"id":"section-1","level":2,"title":"An attractive non-BCMA option, with superiority still an open question"},{"id":"section-2","level":2,"title":"Less persistent GPRC5D toxicity does not resolve the non-ICANS neurologic signal"},{"id":"section-3","level":2,"title":"Post-BCMA placement is attractive, but antigen switching is not an automatic rule"},{"id":"section-4","level":2,"title":"Earlier CAR-T is framed as a remission opportunity, not a guaranteed cure"},{"id":"section-5","level":2,"title":"Referral and access remain limiting even when enthusiasm and center capacity improve"},{"id":"section-6","level":2,"title":"Holding and bridging therapy have different purposes and different constraints"},{"id":"section-7","level":2,"title":"CAR-T deferral prompts risk-adapted alternatives, with substantial supportive-care qualifications"},{"id":"section-8","level":2,"title":"Off-the-shelf alternatives depend on eligibility, sequencing and treatment burden"},{"id":"section-9","level":2,"title":"MRD is discussed as an earlier evidence signal and a treatment-stop question—not a stopping rule"},{"id":"section-10","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3"},"identity":{"accepted_at":"2026-10-09T22:31:55.117816Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-10T00:58:22Z","record_hash":"cbe2f967a5d7e49ebcbe37f91d1a6799eb43c0258d4493f06af753e33b834b9e","release_hash":"7cf6c378989c07c718bc8393e5ed30ab3274a113041e5f3c9e3b9fa60dba4d5b","report_id":"erudio-nct06615479","run_id":"66ba5bf0-1090-4552-96b7-487c1f5ec50b","schema_version":"5.0","slug":"quintessential-2-06615479","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"QUINTESSENTIAL-2 anchors clinicians' discussion of where arlocabtagene autoleucel (arlo-cel), a GPRC5D-directed CAR-T, could fit for adults with relapsed or refractory, lenalidomide-exposed multiple myeloma. Topics include the comparative benefit that would matter against daratumumab, pomalidomide and dexamethasone or carfilzomib and dexamethasone, GPRC5D-related and neurologic toxicity, sequencing around BCMA-directed therapy, earlier CAR-T use and MRD, referral and access, bridging, and options for patients who defer or cannot receive CAR-T. Coverage is limited to the reviewed commentary sources.","meta_description":"10 HCP sources screened · 227 verified claims from 8 sources · 9 findings. Updated 2026-10-09.","person_names_policy":"role_only","sample_findings":[]},"publication":{"approved_at":"2026-10-10T00:58:22Z","approved_by":"Audun Utengen","corrections":[{"affected_ids":[],"date":"2026-10-09T22:51:00Z","summary":"Trial study IDs and short name taken from the registry record"},{"affected_ids":[],"date":"2026-10-09T22:56:00Z","summary":"Preview abstract rewritten to lead with the clinicians' question"},{"affected_ids":[],"date":"2026-10-10T01:11:00Z","summary":"Title-derived honorific removed: “Drs. Sagar Lonial” is now “Sagar Lonial”, as the verified binding names this speaker."},{"affected_ids":[],"date":"2026-10-10T01:11:00Z","summary":"First-name references to bound speakers now use the verified surname (Amrita → Krishnan, Eyal → Lebel, Krina → Patel, Rakesh → Popat)."},{"affected_ids":[],"date":"2026-10-10T01:11:00Z","summary":"“Excalibur” was normalized to “EXCALIBER-RRMM” (NCT04975997) outside quotations."},{"affected_ids":[],"date":"2026-10-10T01:11:00Z","summary":"An editorial bracket follows a transcription-garbled drug name in quotations: “Arlocaptagene autolysin [arlocabtagene autoleucel]”."},{"affected_ids":[],"date":"2026-10-10T01:11:00Z","summary":"An editorial bracket follows a transcription-garbled drug name in quotations: “anita-cel [anito-cel]”."},{"affected_ids":[],"date":"2026-10-10T01:11:00Z","summary":"Held-out review entries now state plainly what the edition does not yet include."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"1.0","scope_and_limits":{"commentary_scope":{"basis":"Reviewed retained sources only; not all HCPs or all public discussion.","empty_source_ids":[],"has_known_gaps":true,"held_out_finds":10,"refresh_due_at":"2026-10-10T22:31:55.117816Z","retrieval_gaps":["commentary:coverage_scope:keyword matches to trial identifier and registry aliases; single-letter acronym variants require planned context in the same indexed chunk; unnamed references or other transcription variants may be absent","commentary:identity_queries:named_sources=13;queries=2","commentary:discovery_screen:discovery-screen-1;candidates=39;admitted=0","commentary:discovery_screened_out:youtube:video_id:IPABT7BYPMA=Discusses the earlier QUINTESSENTIAL trial, not QUINTESSENTIAL-2.,youtube:video_id:8BltPH0agX4=General RRMM proceedings; no indication of this specific trial.,x_thread:conversation_id:1706971426379403695=Discusses 2023 BMS-986393 activity, not this Phase III trial.,x_thread:conversation_id:2097433626376094115=Explicitly describes separate Phase II results in BCMA-exposed patients.,x_thread:conversation_id:2099288746415763610=Specifies registrational Phase II results, not this Phase III study.,youtube:video_id:UDiiHA3P8ng=Generic relapsed-myeloma talk; no trial-specific indication.,x_thread:conversation_id:1861832919184187622=Explicitly covers a separate Phase I study.,youtube:video_id:33tcACcEsQc=General recruiting-studies overview; no sign of this trial.,youtube:video_id:NJ_xFBzjcMQ=Covers a different regimen and newly diagnosed population.,x_thread:conversation_id:1733617867382476972=Discusses earlier BMS-986393 data, not this Phase III trial.,x_thread:conversation_id:1801647305856024959=Reports separate 2024 BMS-986393 results.,youtube:video_id:kzrhL5R1m5g=Broad congress title; snippet does not identify this trial.,youtube:video_id:rIyanNChgVg=General CAR-T coverage; no specific trial identifier or design.,youtube:video_id:IUkkT-zPRks=Names the unrelated DREAMM-9 study.,x_thread:conversation_id:1727787991664316863=Reports earlier BMS-986393 data, not QUINTESSENTIAL-2.,youtube:video_id:WQI0sKHNJYY=Names a different trial and treatment regimen.,x_thread:conversation_id:1733621869239296404=ASH23 GPRC5D CAR-T discussion predates this trial.,youtube:video_id:pctvW79tlb8=Names the separate ReLApsE trial.,podcast:episode_id:030520=Generic myeloma episode; no evidence of this trial.,youtube:video_id:-kH9p3uGbLk=Names the distinct Phase II QUINTESSENTIAL trial, not QUINTESSENTIAL-2.,youtube:video_id:2kGLdACW4Oo=Names a different study and intervention combination.,x_thread:conversation_id:1776409568647536688=Discusses ide-cel approval, not arlo-cel.,x_thread:conversation_id:1731401942268579950=Compares ide-cel with standard treatments, not this trial.,youtube:video_id:pEXTSb1Uj-w=Covers linvoseltamab, not arlo-cel.,x_thread:conversation_id:1733617539618365486=ASH23 BMS-986393 results concern earlier research.,youtube:video_id:0LvQS3DIB7o=Covers newly diagnosed myeloma, a different setting.,podcast:episode_id:c108e4=Broad emerging-therapy discussion; no trial-specific design or identifier.,youtube:video_id:FeGsI9GSq48=Arlo-cel results are mentioned, but not this trial's design.,youtube:video_id:HPTJk4JcAT4=BMS-986393 update lacks evidence it concerns QUINTESSENTIAL-2.,youtube:video_id:tin9j3iVLR8=General arlo-cel overview; no evidence of this trial's design.,youtube:video_id:4hHXv9Y5gWY=Explicitly covers a separate Phase I trial.,youtube:video_id:wXXcSTn2mfg=Explicitly reports results from a separate Phase I trial.,x_thread:conversation_id:2063850533836706233=Explicitly describes updated Phase I data.,youtube:video_id:RrsqehSGRc8=Covers allogeneic BCMA-directed CAR-T, not this intervention.,podcast:episode_id:f4581f=Broad immune-therapy symposium; no specific trial indication.,youtube:video_id:VSjdGeeXb40=ODAC meeting title gives no indication of this trial.,youtube:video_id:3gF-rdBENwg=Explicitly reports Phase I results in a different population.,youtube:video_id:2d_fXwFJx_0=Names a different CAR-T product and study.,youtube:video_id:MT75ls0Crus=BMS-986393 update lacks evidence of this Phase III trial.","Held out after independent review: passages of “Current and Future Care of Patients with Relapsed/Refractory Multiple Myeloma” at 11:51, 14:04, 14:10 (the speaker). What they say is not yet represented in this edition's verified claims.","Held out after independent review: passages of “Current and Future Care of Patients with Relapsed/Refractory Multiple Myeloma” at 51:54 (the speaker). What they say is not yet represented in this edition's verified claims.","Held out after independent review: a passage of “Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances” (the speaker). What it says is not yet represented in this edition's verified claims.","Held out after independent review: a passage of “Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances” (the speaker). What it says is not yet represented in this edition's verified claims.","Held out after independent review: a passage of “Current and Future Care of Patients with Relapsed/Refractory Multiple Myeloma” at 40:56 (Thanos Dimopoulos). What it says is not yet represented in this edition's verified claims.","Held out after independent review: a passage of “Current and Future Care of Patients with Relapsed/Refractory Multiple Myeloma” (the speaker). What it says is not yet represented in this edition's verified claims.","Held out after independent review: a passage of “Current and Future Care of Patients with Relapsed/Refractory Multiple Myeloma” (the speaker). What it says is not yet represented in this edition's verified claims.","Held out after independent review: passages of “Current and Future Care of Patients with Relapsed/Refractory Multiple Myeloma” (the speaker). What they say is not yet represented in this edition's verified claims.","Held out after independent review: passages of “Watch Drs. Sagar Lonial & Krina Patel discuss #MultipleMyeloma updates” at 5:08, 7:22 (Sagar Lonial). What they say is not yet represented in this edition's verified claims."],"source_count":10,"unreadable_unit_ids":[]},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.","10 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.","Out of scope in retained sources: 21 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.","Further source limits: the search also described the trial without its name, to find discussion that does not name it; sources found that way were screened by their titles before any was read; some of those sources were set aside as about other trials.","The reviewed material is not a representative sample of HCP opinion. Discussion without the indexed trial name or aliases, including unnamed references or transcription variants, may be absent; the report therefore cannot establish prevalence or consensus.","No exact-trial publication or standalone protocol was available in the supplied material, and regulatory context for BMS-986393 was incomplete. This limits independent interpretation of the trial-specific questions raised by speakers.","Earlier-study efficacy and safety figures are attributed speaker accounts with differing populations, doses, follow-up or unspecified comparisons. They are not QUINTESSENTIAL-2 results and should not be combined as one estimate.","Anonymous panel passages cannot be assigned to nearby named speakers. Moderator summaries and reported prior responses do not establish individual ownership of votes or preferences.","Several timing statements are forecasts or publication-relative expectations. The report does not reconcile them into a verified enrollment or readout chronology."]},"sources":{"cited_sources":{"by_channel":{"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":1,"x_video":0,"youtube":6},"by_evidence_role":{"commentary":8},"count":8,"evidence_window":{"end":"2026-10-07","start":"2024-12-13"},"retrieval_snapshot":"2026-10-09T21:25:22.624300Z","timeline":[{"count":1,"week":"2024-W50"},{"count":1,"week":"2025-W24"},{"count":1,"week":"2025-W38"},{"count":1,"week":"2025-W40"},{"count":1,"week":"2025-W52"},{"count":1,"week":"2026-W04"},{"count":1,"week":"2026-W34"},{"count":1,"week":"2026-W41"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06615479:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06615479:context","quote_policy":"short_quote_link_out"},{"id":"openfda:c961a1ac-6705-4756-9abc-9d84a6fcb5c8:20260903","quote_policy":"short_quote_link_out"},{"id":"openfda:cf5255cc-91fd-4132-973b-764dba142eae:20241014","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:358c31","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1867635503379403139:de0d9860-5231-4672-a480-a9bf0a5ee6dd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1911130924126699842:1093665f-f413-4c2c-a8a8-84ba2953a2ba","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098803746012586167:dd739f78-0b9a-4126-84f9-c062b8b44b51","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:6hOEBEAHxIw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Itgs0BY1V_I","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:M3xBxNyVLus","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ieT-Wo-ktAk","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ncaXf81_aQQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:pXwPqq1ysHY","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":3,"x_video":0,"youtube":6},"by_evidence_role":{"commentary":10},"count":10,"evidence_window":{"end":"2026-10-07","start":"2024-12-13"},"retrieval_snapshot":"2026-10-09T21:25:22.624300Z","timeline":[{"count":1,"week":"2024-W50"},{"count":1,"week":"2025-W15"},{"count":1,"week":"2025-W24"},{"count":1,"week":"2025-W38"},{"count":1,"week":"2025-W40"},{"count":1,"week":"2025-W52"},{"count":1,"week":"2026-W04"},{"count":1,"week":"2026-W34"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W41"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"arlocabtagene autoleucel","slug":"arlocabtagene-autoleucel"},{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"cyclophosphamide","slug":"cyclophosphamide"},{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"fludarabine","slug":"fludarabine"},{"brand_names":["Darzalex"],"label":"daratumumab","slug":"daratumumab"},{"brand_names":["Pomalyst"],"label":"pomalidomide","slug":"pomalidomide"},{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"dexamethasone","slug":"dexamethasone"},{"brand_names":["Kyprolis"],"label":"carfilzomib","slug":"carfilzomib"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Multiple myeloma","slug":"multiple-myeloma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"aliases":["A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma"],"brief_title":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","collaborators":["Celgene Corporation"],"conditions":["Relapsed or Refractory Multiple Myeloma (RRMM)"],"enrollment":{"count":440,"type":"ESTIMATED"},"excluded_lookalike_trials":{"reason":"No owner-reviewed lookalike exclusion list.","status":"not_set"},"interventions":[{"name":"BMS-986393","synonyms":["Arlo-cel"],"type":"DRUG"},{"name":"Cyclophosphamide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Fludarabine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Daratumumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pomalidomide","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Dexamethasone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Carfilzomib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06615479","official_title":"A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2027-12-30","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Progression Free Survival (PFS)","timeFrame":"Up to 5 years after the last participant is randomized"},{"measure":"Minimal residual disease (MRD)-negativity in complete response (CR)","timeFrame":"Up to 1 year after the last participant is randomized"}],"registry_last_updated":"2026-09-15","registry_url":"https://clinicaltrials.gov/study/NCT06615479","short_name":"QUINTESSENTIAL-2","short_name_basis":"registry_title","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","start_date":{"date":"2025-03-12","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"CA088-1007","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}